Viewing Study NCT05904457

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:33 PM
Ignite Modification Date: 2026-02-20 @ 5:58 PM
Study NCT ID: NCT05904457
Status: RECRUITING
Last Update Posted: 2023-06-15
First Post: 2023-06-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
Sponsor: Asan Medical Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Tumors View
None Advanced Solid Tumors View
None Metastatic Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Krebs cycle View
None FH View
None IDH View
None SDH View
None bevacizumab View
None erlotinib View
None cancer View
None aerobic glycolysis View
None brisk View